<DOC>
	<DOCNO>NCT00411528</DOCNO>
	<brief_summary>The objective study assess response patupilone plus prednisone compare docetaxel plus prednisone prostate specific antigen ( PSA ) patient metastatic hormone refractory prostate cancer . Additionally , study assess response measureable disease effect patient-reported outcome .</brief_summary>
	<brief_title>Efficacy Safety Patupilone Men ( ≥18 Years ) With Metastatic Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Inclusion criterion : Must ≥ 18 year age Confirmed documented diagnosis prostate cancer Confirmed document evidence progression disease ( hormone refractory ) Low testosterone level Chemotherapynaïve Exclusion criterion : Recent radiation therapy ( within 4 week ) Known brain metastasis Peripheral neuropathy Active diarrhea Significant illnesses heart disease , diabetes , chronic uncontrolled infection Allergic reaction patupilone docetaxel prednisone similar compound Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Hormone Refractory</keyword>
	<keyword>patupilone</keyword>
	<keyword>docetaxel</keyword>
</DOC>